Abstracts tagged "autoimmune diseases and systemic lupus erythematosus (SLE)"

Abstract Number: 1015 • 2019 ACR/ARP Annual Meeting
Evidence for Substantial Immune Activation in Asymptomatic ANA Positive Individuals
Emma Van Lieshout¹, Dennisse Bonilla ², Zahi Touma ³, Arthur Bookman ⁴, Linda Hiraki ⁵, Zareen Ahmad ⁶, Sindhu Johnson ⁷, Earl D. Silverman ⁸ and Joan Wither ⁹, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, Canada, ⁴University Health Network - Toronto Western Hospital, Toronto, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, ⁶Mount Sinai Hospital, Toronto, Canada, ⁷Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ⁹University Health Network, Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Systemic autoimmune rheumatic diseases (SARD) including Sjogren’s Disease (SjD), Systemic Sclerosis (SSc) and Systemic Lupus Erythematosus (SLE) are characterized by the production of anti-nuclear…
Abstract Number: 2658 • 2017 ACR/ARHP Annual Meeting
4-Hydroxy-2-Nonenal Serum Protein-Adducts and Anti-4-Hydroxy-2-Nonenal-Protein Adduct Antibodies in SLE
Biji T Kurien^1,2,3 and R. Hal Scofield⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, complex disease and autoantibodies to self-antigens are a characteristic feature of the disorder. Our group and others…
Abstract Number: 883 • 2013 ACR/ARHP Annual Meeting
Sex Bias In Autoimmune Diseases: Increased Risk Of 47,XXX In Systemic Lupus Erythematosus (SLE) and Sjögren’s Syndrome (SS) Supports The Gene Dose Hypothesis
Ke Liu¹, Kenneth M. Kaufman^2,3, Judith A. James^4,5, Roland Jonsson^6,7, Biji T. Kurien^4,5,8, Xavier Mariette⁹, Joan T. Merrill¹⁰, Roald Omdal¹¹, Maureen Rischmueller^12,13, Timothy J. Vyse¹⁴, Marie Wahren-Herlenius¹⁵, Torsten Witte¹⁶, Christopher J. Lessard^4,5, Sarah L. Zimmerman¹⁷, Susan D. Thompson¹⁸, Gideon Hirschfield¹⁹, Gang Xie^20,21, Courtney G. Montgomery^8,22, Wan-Fai Ng²³, Gunnel Nordmark²⁴, Patrick M. Gaffney^4,8, Katherine A. Siminovitch^20,25, Kathy L. Sivils^4,26, Slegen (International Consortium For The Genetics Of SLE)²⁷ and R. Hal Scofield^4,5,28, ¹Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, ²U.S. Department of Veterans Affairs Medical Center, Cincinnati, OH, ³1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ⁷Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁸U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁹Paris-Sud University, Paris, France, ¹⁰Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹²Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, ¹³Discipline of Medicine, University of Adelaide, Adelaide, Australia, ¹⁴Division of Genetics and Molecular Medicine and Division of Immunology, Infection and Inflammatory Disease, King's College London, London, United Kingdom, ¹⁵Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹⁶Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ¹⁷Divison of human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁸Division and Center for Autoimmune Disease Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁹Centre for Liver Research, Institute of Biomedical Research, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ²⁰Mount Sinai Hospital, Toronto, ON, Canada, ²¹University Of Toronto, Toronto, ON, Canada, ²²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²³Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom, ²⁴Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²⁵University of Toronto, Toronto, ON, Canada, ²⁶University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁷Center for Autoimmune Genomics and Etiology and Rheumatology Division, International Consortium For The Genetics Of Systemic Lupus Erythematosus, Cincinnati, OH, ²⁸US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Female preponderance is a hallmark of most autoimmune diseases, the mechanism for which is unknown. We hypothesize that this is a consequence of a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].